Please use this identifier to cite or link to this item: https://doi.org/10.1007/s00520-010-0843-8
Title: Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy
Authors: Chan, A. 
Fu, W.H.
Shih, V.
Coyuco, J.C.
Tan, S.H.
Ng, R.
Keywords: Breast cancer
Colony-stimulating factors
Cyclophosphamide
Docetaxel
Febrile neutropenia
G-CSF
Issue Date: Apr-2011
Citation: Chan, A., Fu, W.H., Shih, V., Coyuco, J.C., Tan, S.H., Ng, R. (2011-04). Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Supportive Care in Cancer 19 (4) : 497-504. ScholarBank@NUS Repository. https://doi.org/10.1007/s00520-010-0843-8
Abstract: Background: Data from US Oncology Adjuvant Trial 9735 has shown that four cycles of docetaxel plus cyclophosphamide (TC) improved disease-free and overall survival when compared against doxorubicin and cyclophosphamide (AC) in early-stage breast cancer. The febrile neutropenia (FN) rate was 4% in this study without primary granulocyte colony-stimulating factors (G-CSF) prophylaxis. However, the incidence of docetaxel-induced myelosuppression is recognized to be higher among Asian population. Hence, this study was designed to evaluate the impact of G-CSF to reduce FN-related events in Asian cancer patients treated with TC. Method: This retrospective cohort study was conducted on Asian breast cancer patients who have received intravenous docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 between 2006 to 2008. Patients did not receive oral antibiotic prophylaxis, and prophylactic G-CSF after chemotherapy was prescribed under the discretion of the primary oncologist. Results: During cycle 1 of chemotherapy, 6.3% patients received G-CSF manifested FN, while 25% patients who did not receive G-CSF manifested FN (RR=0.252, 95% CI 0.102 to 0.622). Introduction of G-CSF as primary prophylaxis provided an absolute risk reduction of FN events by 18.7%. Chemotherapy doses were maintained throughout all cycles. Patients with pretreatment white blood cell counts (WBC) below 6.0×103/mm3 and absolute neutrophil counts (ANC) below 3.1×103/mm3 were associated with higher rates of FN during Cycle 1 (p=0.009, p=0.007). Conclusions: Our findings indicate that TC was associated with higher rates of FN than reported in the clinical trial. The 25% incidence fulfills the requirement of primary prophylaxis with G-CSF. Routine administration of G-CSF is highly recommended to reduce the rates of FN in breast cancer patients receiving TC. © 2010 Springer-Verlag.
Source Title: Supportive Care in Cancer
URI: http://scholarbank.nus.edu.sg/handle/10635/106023
ISSN: 09414355
DOI: 10.1007/s00520-010-0843-8
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

32
checked on Aug 17, 2018

WEB OF SCIENCETM
Citations

25
checked on Aug 1, 2018

Page view(s)

38
checked on Jul 27, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.